Every material Form 8-K VOLITIONRX LTD has filed with the SEC since September 02, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
VolitionRx paid $500,000 in cash toward the principal of its $2.4 million senior secured convertible note held by Lind Global Asset Management XII LLC, leaving a balance of $706,667. Under an October 23, 2026 waiver, Lind agreed not to convert the note before January 1, 2027 unless the closing share price reaches $0.275, and the November and December 2026 repayments were deferred. The company says the moves reduce debt and pause conversion rights, which bear on potential share dilution, though the deferrals show the scheduled payments were pushed back.
$500,000 cash prepayment of principal on the note, with $706,667 remaining outstanding
Lind agreed not to exercise conversion rights on or before January 1, 2027, unless the closing price equals or exceeds $0.275 per share
November and December 2026 monthly repayments deferred and kept in outstanding principal
Waiver dated October 23, 2026; company press release issued October 27, 2026
VolitionRX prepaid in cash the outstanding principal of its $7.5 million senior secured convertible note issued to Lind Global Asset Management XII LLC, with the prepayment made on September 11, 2026, and the company says no further amounts remain outstanding under that note. The company says the prepayment prevents further potential dilution to stockholders from the note, and the separate $2.4 million 2026 Note remains in effect.
Prepayment of approximately $422,000 made September 11, 2026 under Section 1.4.1 of the 2025 Note
The $7.5 million 2025 Note, dated May 20, 2025, is fully satisfied; the 2026 Note remains outstanding at $2,041,667 per the press release
CEO Cameron Reynolds said the note was retired more than eight months ahead of its originally scheduled maturity
VolitionRx entered a waiver and consent with its lender Lind Global Asset Management XII on September 2, 2026. Lind agreed that all at-the-market (ATM) stock sales, including amounts above the $10 million annual cap, count as permitted sales and waived related default and remedy rights tied to those sales. The waiver removes a potential default risk for the company while it sells shares under its ATM program, but it also means share sales above the prior cap can proceed without the lender's objection.
Lind consented to all ATM Agreement sales, including amounts above $10 million in a calendar year, as Permitted ATM Sales.
Lind waived remedies tied to ATM sales under the Purchase Agreement and both Notes, including rights to accelerate amounts due.
Conversion Price of the Notes and Exercise Price of the Warrants were adjusted for ATM sales through August 28, 2026; sales after that date are excluded from adjustment.
The Notes are $7.5 million (May 15, 2025) and $2.4 million (January 7, 2026); the warrants cover 651,042 and 350,018 shares.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every VOLITIONRX LTD filing is on SEC EDGAR ↗. 8-K briefs of other companies →